You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
[2026 ENA]Avistone Biotechnology Presents First Data Disclosure Internationally for ANS02, a Fourth-Generation EGFR Inhibitor
The 38th EORTC–NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) — will be held in person from November 18 to 20, 2026, at the CCIB in Barcelona, Spain. At this year's meeting, Avistone Biotechnology Co., Ltd. will present the first disclosure of preclinical and early clinical data for ANS02, its self-discovered fourth-generation EGFR inhibitor in a poster session.

Poster Title
ANS02: A Novel Macrocyclic, Non-Covalent, CNS-Penetrant, Mutant-Selective EGFR TKI in NSCLC
Poster Board Number
PB-093
Authors
Gong Li, Peilong Zhang, Linna Li, Ruiya Zhang, Shutan Liao, Peipei Yang, Hepeng Shi
Abstract Summary
ANS02 is a potent, highly selective, fourth-generation EGFR tyrosine kinase inhibitor (TKI) with excellent CNS penetration. It demonstrates broad-spectrum and robust inhibitory activity against classical EGFR mutations, resistance mutations including T790M and C797S, a range of compound mutations, and atypical EGFR variants. ANS02 only weakly inhibits wild-type EGFR, conferring higher mutant selectivity and a wider safety window.
In multiple NSCLC mouse models harboring EGFR-sensitizing and resistance mutations, ANS02 exhibited potent antitumor efficacy with a favorable safety profile. Complete tumor regression was achieved in third-generation EGFR TKI-resistant C797S-mutant models:
(1)In a patient-derived xenograft (PDX) model carrying EGFR Ex19del/T790M/C797S mutations, oral dosing at 3 mg/kg once daily (QD) induced complete tumor regression.
(2)In an engineered Ba/F3 EGFR L858R/C797S subcutaneous cell line-derived xenograft (CDX) model, oral dosing at 6 mg/kg QD induced complete tumor regression. In addition, in an EGFR-sensitizing mutation (EGFR Ex19del) model, oral dosing at 3 mg/kg QD induced complete tumor regression, ANS02 substantially outperforming osimertinib at the same dose. Notably, in an intracranial implantation model using the NCI-H1975-luc cell line (EGFR L858R/T790M), oral dosing at 6 mg/kg and 12 mg/kg QD achieved intracranial tumor growth inhibition (TGI) rates of 99% and >100%, respectively, demonstrating marked intracranial antitumor activity.
A Phase I clinical trial of ANS02 is currently underway across multiple study sites in China and the United States. Antitumor activity has been observed in all dose cohorts that have completed at least one tumor assessment. Among these trials, one participant harboring EGFR Ex19del/C797S-positive disease achieved a 39.4% reduction in target lesions from baseline after 6 weeks of oral ANS02 at 40 mg QD.
Another participant harboring EGFR Ex19del/T790M/C797S mutations achieved a 71.8% reduction in target lesions from baseline after 6 weeks of oral ANS02 at 80 mg QD.
As of press time, no Grade ≥3 adverse events (AEs) have been reported in the study.
Forward-Looking Statements
The forward-looking statements made in this article relate only to events or information as of the date on which such statements are made in this article. Except as required by law, after the date of making the forward-looking statements, we shall have no obligation to update or publicly revise any forward-looking statements or unforeseen events, regardless of whether new information, future events or other circumstances arise. Please read this article carefully and understand that our actual future results or performance may differ materially from expectations. All statements contained in this article are made as of the publication date of this article and are subject to change in light of future developments.